HCV treatment found safe and effective in individuals with kidney disease

September 7, 2017, American Society of Nephrology
This image shows a cross section of a kidney. Credit: Holly Fischer/Wikipedia

A new study indicates that direct-acting antiviral therapy is safe and effective in patients with chronic kidney disease (CKD) and Hepatitis C virus (HCV) infection. The study, which appears in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN), also found that treatment may help improve some patients' kidney function.

HCV infection—which often causes liver disease—is common in with CKD, and it increases their risk of progressing to failure. Sofosbuvir is a potent direct-acting antiviral therapy against HCV, but concerns about potential kidney toxicity have been raised, particularly in patients with CKD.

To determine the safety and efficacy of sofosbuvir in patients with CKD, Meghan Sise, MD, MS (Massachusetts General Hospital) and her colleagues studied 98 patients with stages 1-3 CKD who received sofosbuvir-based therapy in a large healthcare system.

Overall sustained virologic response (which is synonymous with cure of HCV infection) was 81%, and average kidney function while on the treatment was stable. Patients with more advanced CKD were more likely to be cured of HCV infection than those with mild CKD. In addition, patients with advanced CKD who were cured of HCV infection experienced an improvement in their kidney function following treatment. Sofosbuvir was reasonably well tolerated: were common (81%), but serious adverse events (17%) and treatment discontinuations (8%) were uncommon. Also, there was no detectable effect of the degree of CKD on the rate of adverse events.

Larger studies are needed to determine if eradication of HCV with direct-acting antiviral therapy slows or prevents progression to end stage kidney disease in patients with CKD and HCV.

"The use of direct-acting antiviral therapy in patients with Hepatitis C infection has transformed the illness into a curable one. This study shows that these medications can be safely and effectively used in patients with stage 1-3 ," said Dr. Sise.

In an accompanying editorial, Richard Johnson, MD (University of Colorado) and Michiko Shimada, MD, PhD (Hirosaki University Graduate School of Medicine, in Japan) noted that there are other antiviral drugs that are effective in patients with CKD and HCV, and unlike sofosbuvir, they are not eliminated by the kidneys. Therefore, additional research on the effects of different antivirals in patients with compromised are needed. "We predict that HCV, like hepatitis B virus and HIV, will slowly disappear as a major medical problem for patients with renal disease," they wrote.

Explore further: Antiviral drug prevents recurrence of hepatitis C in liver transplant patients

More information: "Effect of Sofosbuvir-based Hepatitis C Virus Therapy on Kidney Function in Patients with Chronic Kidney Disease," Clinical Journal of the American Society of Nephrology (2017). DOI: 10.2215/CJN.02510317

Related Stories

Antiviral drug prevents recurrence of hepatitis C in liver transplant patients

January 10, 2017
Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II ...

Non-specialists can expand hepatitis C treatment access

August 8, 2017
(HealthDay)—Non-specialists, including primary care providers (PCPs) and nurse practitioners (NPs), safely and effectively administer direct-acting antiviral therapy for hepatitis C virus (HCV) to patients seen in federally ...

Sofosbuvir plus ledipasvir seems effective for HCV genotype 1

November 4, 2014
(HealthDay)—For patients with chronic hepatitis C virus genotype 1 (HCV GT-1) infection who are ineligible for interferon therapy, and who relapsed after sofosbuvir and ribavirin treatment, sofosbuvir plus ledipasvir is ...

All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

April 23, 2015
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...

Genetic markers may predict which HCV, cirrhosis patients improve with treatment

May 6, 2017
Genotyping of patients with advanced cirrhosis from hepatitis C virus could help health-care professionals predict the likelihood of improvement after successful hepatitis C treatment, thus minimizing the need for liver transplants. ...

Improved glycemic control with eradication of hepatitis C

July 7, 2017
(HealthDay)—For patients with type 2 diabetes, direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) is associated with improved glycemic control and reduced antidiabetic medication use, according to a study ...

Recommended for you

Novel molecular target to prevent scarring of the lung blood vessels identified

June 13, 2018
Pulmonary arterial hypertension, a severe form of cardiopulmonary disease in which the arteries that transport blood from the heart to the lungs become thickened, constricted, and scarred, is a disease for which there is ...

Fast-acting cholera vaccine could curb outbreaks

June 13, 2018
A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest. The rapid protection offered by this designer vaccine may one day limit the spread of cholera outbreaks, ...

Lineage of TB traced and compared to early human migration

June 13, 2018
A team of researchers from the University of Wisconsin, the University of Iowa and the Norwegian Institute of Public Health has carried out genetic studies of tuberculosis to learn more about its lineage and to compare it ...

Finally, hope for a syphilis vaccine

June 12, 2018
Despite efforts to eradicate it, syphilis is on the rise. Until now, most health agencies focused on treating infected people and their sex partners but new discoveries may make a vaccine possible, UConn Health researchers ...

How to slow down Ebola—Virologists use 'genetic trees' to evaluate intervention strategies

June 12, 2018
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just reveal how the Ebola virus was able to evolve—it also reveals which events and preventive measures accelerated or slowed down its spread. These findings ...

Small children and pregnant women may be underdosed in current malaria regimen

June 12, 2018
Current recommended dosing regimens for the most widely used treatment for uncomplicated Plasmodium falciparum malaria may be sub-optimal for the most vulnerable populations of patients, according to a study published this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.